UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.

Twelve days after GSK secured a key win in Florida, with a state court tossing expert testimony on the cancer-causing ...

GSK shares jumped ... claims its Zantac heartburn drug causes cancer. The Delaware Supreme Court said it will review a decision by a lower court to let an upcoming trial hear evidence from ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn ...

That win closely followed a settlement in a separate Zantac prostate cancer ... personal injury case to go to trial, Chicago jurors in late May absolved GSK and Boehringer Ingelheim of fault ...

Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical ... In December 2022, approximately 50,000 Zantac cases were dismissed during a pre-trial hearing in Florida.

Plaintiffs in the case have argued that ranitidine can cause cancer. The drug was marketed for years by GSK (GSK) under the brand name Zantac and by various generic drugmakers. GSK (GSK ...

Investing.com -- Shares of GSK ... trial. At 4:31 am (0831 GMT), GSK was trading 1.5% higher at £1,642.11. The litigation at the center of this legal battle revolves around allegations that ...

The US state of Delaware's highest court will hear an appeal by GSK and other drugmakers seeking to end over 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. The ...

Zamboni is expected to say the 'Tanner study - which was not submitted to the FDA until 2019 - provides evidence that GSK knew about Zantac's potential health impacts, but failed to make the ...